Advances in venom peptide drug discovery: where are we at and where are we heading?. (3rd October 2021)

• Record Type: Journal Article
• Authors: Smallwood, Taylor B.; Clark, Richard J.
• Is Part Of: Expert opinion on drug discovery. Volume 16:Number 10(2021)
• Page Start: 1163
• Page End: 1173
• Publication Date: 2021-10-03
• Subjects: Disulfide bond -- drug -- peptide -- therapeutics -- venom; 615.1
• DOI: 10.1080/17460441.2021.1922386
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction : Animal venoms are a complex mixture of bioactive molecules that have evolved over millions of years for prey capture and defense from predators. Venom consists of many different types of molecules, with disulfide-rich peptides being a major component in most venoms. The study of these potent and highly selective molecules has led to the development of venom-derived drugs for diseases such as type 2 diabetes mellitus and chronic pain. As technologies have improved, more bioactive peptides have been discovered from venomous animals. Many of these molecules may have applications as tools for understanding normal and disease physiology, therapeutics, cosmetics or in agriculture. Areas covered : This article reviews venom-derived drugs approved by the FDA and venom-derived peptides currently in development. It discusses the challenges faced by venom-derived peptide drugs during drug development and the future for venom-derived peptides. Expert opinion : New techniques such as toxin driven discovery are expanding the pipeline of venom-derived peptides. There are many venom-derived peptides currently in preclinical and clinical trials that would have remained undiscovered using traditional approaches. A renewed focus on venoms, with advances in technology, will broaden the diversity of venom-derived peptide therapeutics and expand our knowledge of their molecular targets.